FDA Recalls Finder

FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
22 January 2010, 2:35 pm

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

Source: Food and Drug Administration--Press Releases